Thymulin

Also known as: FTS, Facteur Thymique Serique

**Mechanism of Action** Thymulin (Facteur Thymique Serique, FTS) is a zinc-dependent nonapeptide secreted by thymic epithelial cells. Its biological activity requires chelation with zinc ions, forming an active complex that binds to high-affinity receptors on T-cell precursors and mature lymphocytes. This binding promotes T-cell differentiation, maturation, and functional modulation, including enhanced cytokine secretion (e.g., IL-2, IFN-γ) and regulation of CD4+/CD8+ ratios. Additionally, thymulin exerts analgesic effects via opioid receptor pathways and anti-inflammatory actions through suppression of pro-inflammatory mediators such as TNF-α and IL-1β. **Key Research Findings** Preclinical studies demonstrate thymulin’s immunomodulatory capacity in models of immunodeficiency, autoimmunity, and infection. In aged or thymectomized animals, exogenous thymulin restores T-cell numbers and function. Research also highlights its neuroprotective and anti-nociceptive properties, with reduced pain behavior in inflammatory and neuropathic pain models. Anti-inflammatory effects are linked to downregulation of NF-κB signaling and oxidative stress markers. However, no human clinical trials have been completed, and data remain limited to in vitro and animal studies. **Clinical Relevance** Thymulin’s potential applications include immune restoration in aging, HIV, or post-transplant settings, as well as adjunctive therapy for chronic inflammatory or pain conditions. Its zinc dependency poses formulation challenges, and bioavailability in humans is uncharacterized. Without clinical validation, therapeutic use remains speculative. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides